IMM - Immutep Limited
- Thread starter ozewolf
- Start date
- Joined
- 27 April 2009
- Posts
- 40
- Reactions
- 0
Hi I am a trader (day trade & or swing trader) I hold PRR recent purchase at .062 100,000 purchased last friday. Today purchased another 100,000 at .074 Tomorrow is my sell day whether at a loss or profit as plan is to sell prior to the release of expected announcement on the U.S. market.
Reading the map eg chart, big rally on the 21st April to the 22nd then Doji on the 22nd high rejected and sold down to near the close. Then a try for lower prices, on the 23rd then on the 24th an inside day closing at the high (suggests buyers are back in control).
Today the 27th (next trading day) pulled back up over .07 being the low for the day. Note this was the low of the day of the Doji on the 22nd. .07 now seen to be support and the high of the 22nd to be retested (IMO). Tomorrow night U.S. markets i am lead to believe there will be an important announcement to be made that could influence this stock. (Buy on Rumor sell on fact).
I speculate that tomorrow will retest the high and may even break through on the news, however I am a chartist and only use fundamentals to support my map reading. Therefore i will be out tomorrow with a tidy profit if I am correct. If i am wrong I do then not much to loose as will stop out. See map (chart below)
Note Day trading and Swing trades are high risk speak with your broker before taking a trade.
Well that trade went belly up, early in the morning ASX release advising PRR had generously sold a large parcel of shares for 2.5c from memory. Anyway anticipated things not going according to plan so watched for a few minutes and sold out at .072 overall still made a profit. The main thing to remember as a trader, is remember why you entered and if something changes for the worse get out! Thus it was a successful trade even though did not make what i had anticipated.
Attachments
Bio Market in US...very impressive gains...
Can PRR do same ??
Cancer vaccine makers rocket on Dendreon news
BOSTON (MarketWatch) -- Shares of a handful of cancer vaccine developers got a much-needed boost on Tuesday after Dendreon Corp. reported positive clinical results for its prostate cancer treatment Provenge, which has had difficulties winning U.S. regulatory approval.
Shares of Seattle-based Dendreon Corp. (DNDN) rocketed almost 160% to $19.00 in late morning trading, after reaching an earlier high of $22.10. The shares had been halted since late Monday in advance of the news.
Early Tuesday, Dendreon said that a key Phase III clinical trial had shown Dendreon helped extend the lives of men with advanced prostate cancer. While the company didn't specify at this time how much longer the patients lived, it said it would release further details at a medical meeting slated for April 28.
Dendreon shares have traded wildly since 2007, when the Food and Drug Administration declined to approve Provenge, stating it needed more supporting evidence. The FDA's decision horrified Dendreon investors, who were heartened by a positive recommendation issued by an FDA advisory panel on the drug just two months before the agency's final decision.
While the FDA is not bound to the recommendations of its advisory committees, it generally follows them.
Provenge is a member of a new class of cancer therapeutics called vaccines because they use human cells to elicit a strong immune response.
Dendreon's news also stoked shares of other cancer-vaccine companies that have likewise experienced setbacks for their products in recent years.
Shares of Antigenics Inc. (AGEN), which received a Nasdaq delisting warning notice a few months ago, saw its shares shoot up 62% to 72 cents a share.
Antigenics' Oncophage therapy is currently approved only in Russia, where it is still seeking commercial partners and government reimbursement. While Antigenics has filed for approval in Europe, it has yet to do so in the U.S.
Also gaining were shares of Cell Genesys Inc. (CEGE), up 31% at 46 cents. The company has been developing a product called GVAX to treat a variety of cancers.
Cell Genesys discontinued a Phase III clinical trial of GVAX for prostate cancer last summer due to disappointing results.
Can PRR do same ??
Cancer vaccine makers rocket on Dendreon news
BOSTON (MarketWatch) -- Shares of a handful of cancer vaccine developers got a much-needed boost on Tuesday after Dendreon Corp. reported positive clinical results for its prostate cancer treatment Provenge, which has had difficulties winning U.S. regulatory approval.
Shares of Seattle-based Dendreon Corp. (DNDN) rocketed almost 160% to $19.00 in late morning trading, after reaching an earlier high of $22.10. The shares had been halted since late Monday in advance of the news.
Early Tuesday, Dendreon said that a key Phase III clinical trial had shown Dendreon helped extend the lives of men with advanced prostate cancer. While the company didn't specify at this time how much longer the patients lived, it said it would release further details at a medical meeting slated for April 28.
Dendreon shares have traded wildly since 2007, when the Food and Drug Administration declined to approve Provenge, stating it needed more supporting evidence. The FDA's decision horrified Dendreon investors, who were heartened by a positive recommendation issued by an FDA advisory panel on the drug just two months before the agency's final decision.
While the FDA is not bound to the recommendations of its advisory committees, it generally follows them.
Provenge is a member of a new class of cancer therapeutics called vaccines because they use human cells to elicit a strong immune response.
Dendreon's news also stoked shares of other cancer-vaccine companies that have likewise experienced setbacks for their products in recent years.
Shares of Antigenics Inc. (AGEN), which received a Nasdaq delisting warning notice a few months ago, saw its shares shoot up 62% to 72 cents a share.
Antigenics' Oncophage therapy is currently approved only in Russia, where it is still seeking commercial partners and government reimbursement. While Antigenics has filed for approval in Europe, it has yet to do so in the U.S.
Also gaining were shares of Cell Genesys Inc. (CEGE), up 31% at 46 cents. The company has been developing a product called GVAX to treat a variety of cancers.
Cell Genesys discontinued a Phase III clinical trial of GVAX for prostate cancer last summer due to disappointing results.
- Joined
- 27 April 2009
- Posts
- 40
- Reactions
- 0
I dropped this stock when announcement that they issued shares for .025 for capital raising and since then has had not such good news but will look for another entry.
SPP announced today at $0.070 per share up to $5000. Current share price is $0.068.
I can think of two reasons why it is higher than current market price: management no longer need the cash, or management expect it to be over $0.070 by the time the offer closes.
I can think of two reasons why it is higher than current market price: management no longer need the cash, or management expect it to be over $0.070 by the time the offer closes.
- Joined
- 27 April 2009
- Posts
- 40
- Reactions
- 0
The third reason was explained in the offer, I guess at time of preparation they did not expect the price to fall, however after their announcement to obtain fundings by providing shares at .025 from memory it spooked the price down to where it is now.
See below an exert from their offer!
6. Offer Price
The offer price for each Share to be issued under the SPP is $0.07. This price is less than
the market price of ordinary shares in Prima traded on ASX during a specified period in the
30 days prior to the Record Date. The maximum market price of ordinary shares in Prima
traded on ASX during that period was $0.11.
See below an exert from their offer!
6. Offer Price
The offer price for each Share to be issued under the SPP is $0.07. This price is less than
the market price of ordinary shares in Prima traded on ASX during a specified period in the
30 days prior to the Record Date. The maximum market price of ordinary shares in Prima
traded on ASX during that period was $0.11.
- Joined
- 8 April 2009
- Posts
- 8
- Reactions
- 0
Could someone pls post this on Hot C0pper?
PRR followers ... need your help !!
I have a few questions that I would like to post on Hot C0pper forum (since it is busier on the PRR discussion front), but my ID is suspended for now reason and support are not answering mails.
Could someone from this thread please (if you have an account on HC) post my questions there on my behalf?
=======================================================
This is from "planethowells" who has been suspended (again) on HC for no reason so cannot post this directly himself.
planethowells: I am a holder of PRR and a strong believer in their imminent positive gear up to partnering, takeover, IND approval etc. But, I have a question.
I follow the PRR posts on HC daily (remember I cannot participate because of those pesky support dudes).
1) Has anyone got a truly clear view about PRRs patent portfolio and it's scope in terms of rights on this technology application to other cancers and countries that have granted the patents ? ... I have only managed to find info in posts but it's comment rather than published articles.
2) In a presentation from May 2009 on Dendreon's own website (Bank of America and Merrill Lynch 2009 Health Care Conference), one of the slides mentions further application of their technology and the cancers it can be applied to. Ovarian cancer is mentioned. Is Dendreon targeting Mucin-1 protein?. Mucin-1 is not mentioned. If so, does anyone see this as a worry for PRR ? ...does PRR have the patents/rights for drug that target the Mucin-1 protein ?. If yes, how extensive (worldwide) ?
3) In addition to that, Dendreon has in phase I, a drug called Neuvenge which seems to be targeted at Ovarain cancer (among others). Not sure if this is based on Mucin-1 protein (I think not). But, does anyone know if this is a threat to PRR ?
see slide 23 at this link.
http://www.veracast.com/webcasts/bas/healthcare09/id79104527.cfm
4) They mention (on slide 29) "Significant commercial potential: 100% worldwide rights". Does that challenge PRRs patents ?
Will really appreciate it if someone is able to help clarify PRR has nothing to worry about (I'm sure it's the case judging by the immensely positive posts here regarding PRR).
Just a final note. I post this not to generate any picture that PRR may have issues to get their market - I simply want to get clearest understand so that I (and we all) can relax ;-)
Thanks *planethowells*
=======================================================
PRR followers ... need your help !!
I have a few questions that I would like to post on Hot C0pper forum (since it is busier on the PRR discussion front), but my ID is suspended for now reason and support are not answering mails.
Could someone from this thread please (if you have an account on HC) post my questions there on my behalf?
=======================================================
This is from "planethowells" who has been suspended (again) on HC for no reason so cannot post this directly himself.
planethowells: I am a holder of PRR and a strong believer in their imminent positive gear up to partnering, takeover, IND approval etc. But, I have a question.
I follow the PRR posts on HC daily (remember I cannot participate because of those pesky support dudes).
1) Has anyone got a truly clear view about PRRs patent portfolio and it's scope in terms of rights on this technology application to other cancers and countries that have granted the patents ? ... I have only managed to find info in posts but it's comment rather than published articles.
2) In a presentation from May 2009 on Dendreon's own website (Bank of America and Merrill Lynch 2009 Health Care Conference), one of the slides mentions further application of their technology and the cancers it can be applied to. Ovarian cancer is mentioned. Is Dendreon targeting Mucin-1 protein?. Mucin-1 is not mentioned. If so, does anyone see this as a worry for PRR ? ...does PRR have the patents/rights for drug that target the Mucin-1 protein ?. If yes, how extensive (worldwide) ?
3) In addition to that, Dendreon has in phase I, a drug called Neuvenge which seems to be targeted at Ovarain cancer (among others). Not sure if this is based on Mucin-1 protein (I think not). But, does anyone know if this is a threat to PRR ?
see slide 23 at this link.
http://www.veracast.com/webcasts/bas/healthcare09/id79104527.cfm
4) They mention (on slide 29) "Significant commercial potential: 100% worldwide rights". Does that challenge PRRs patents ?
Will really appreciate it if someone is able to help clarify PRR has nothing to worry about (I'm sure it's the case judging by the immensely positive posts here regarding PRR).
Just a final note. I post this not to generate any picture that PRR may have issues to get their market - I simply want to get clearest understand so that I (and we all) can relax ;-)
Thanks *planethowells*
=======================================================
Most latest news about someone being in contact with M. R. .... again all positive (you would believe)....
Martin Rogers, Director PRR, was kind enough to reply on Sunday to an email from me yesterday, (which I read today after work) and to reply again tonight giving his permission for me to post it here. (Seemed unethical not to ask first)
He asked me to include a note that the information is from previous 2007 disclosed information (apart from his comment about the current USA trip, of course).
I contacted him to try to dispel some uncertainty I had about the Biomira rights and PRR's rights to CVAC and he has done so most satisfactorily. Maybe other already knew these facts, but I did not. He also volunteered some comment on the IP coverage and a positive comment about the current US trip.
This was his full reply:
"Biomira don't exist as a company anymore and the rights have been sold to Merck Sharpe & Dome.
However, Prima collapsed its relationship with Biomira swapping project ownership for shares in Prima and Prima acquired the worldwide rights for Biomira. This is a very good position for shareholders. Prima owns 100% of CVac. Biomira sold their shares a while back.
It is complex but the patents of Prima articulate the fusion of mucin-1(antigen) and mannan(carbohydrate adjunvant) to the dendritic cells presenting themselves to the immune system. This is a strong IP position to be in.
Currently I just arrived in the US, things are very positive and we should be going through a great process for shareholders over the next 18 months."
Martin Rogers, Director PRR, was kind enough to reply on Sunday to an email from me yesterday, (which I read today after work) and to reply again tonight giving his permission for me to post it here. (Seemed unethical not to ask first)
He asked me to include a note that the information is from previous 2007 disclosed information (apart from his comment about the current USA trip, of course).
I contacted him to try to dispel some uncertainty I had about the Biomira rights and PRR's rights to CVAC and he has done so most satisfactorily. Maybe other already knew these facts, but I did not. He also volunteered some comment on the IP coverage and a positive comment about the current US trip.
This was his full reply:
"Biomira don't exist as a company anymore and the rights have been sold to Merck Sharpe & Dome.
However, Prima collapsed its relationship with Biomira swapping project ownership for shares in Prima and Prima acquired the worldwide rights for Biomira. This is a very good position for shareholders. Prima owns 100% of CVac. Biomira sold their shares a while back.
It is complex but the patents of Prima articulate the fusion of mucin-1(antigen) and mannan(carbohydrate adjunvant) to the dendritic cells presenting themselves to the immune system. This is a strong IP position to be in.
Currently I just arrived in the US, things are very positive and we should be going through a great process for shareholders over the next 18 months."
- Joined
- 27 April 2009
- Posts
- 40
- Reactions
- 0
I have just brought back in, yesterday as looks to have an equilateral triangle forming, which will break out one way or another. From market depth and previous recent interest in this stock I am anticipating the upside.
If wrong I will be stopped out.
The two days i have circled 8th & 11th March very bullish days high & increased volume. Buyers having a strong effect on the price, on the 8th closed on its high with a good range for the day. On the 11th gapped up high outside of the tri but did not sustain, too strong too early.
However it would appear to be coming to a place of decision, up or down. Yesterdays market depth growing on the buyers side, with small sell off end of day when price movement did not occur.. I would say day traders selling off their positions and may reload tomorrow, only time will tell
Target .10 for the greedy and may not reach, I sill be out before that. Stop loss close under .6
If wrong I will be stopped out.
The two days i have circled 8th & 11th March very bullish days high & increased volume. Buyers having a strong effect on the price, on the 8th closed on its high with a good range for the day. On the 11th gapped up high outside of the tri but did not sustain, too strong too early.
However it would appear to be coming to a place of decision, up or down. Yesterdays market depth growing on the buyers side, with small sell off end of day when price movement did not occur.. I would say day traders selling off their positions and may reload tomorrow, only time will tell
Target .10 for the greedy and may not reach, I sill be out before that. Stop loss close under .6
Attachments
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
Of course im holding, i brought 1k at .016, made about 3k so far, and still holding, im sure they are going to go up more... be patient
Does any one know when the FDA will make its final decision in regards to this vaccine. How fare along are they in their 3rd clinical trial when will that be finished. The company doesn't seem to keep its investors informed it would help if they made more announcements.
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
Whats the go with Prima, up 20% or so in the last two days, any news sneaking through that we haven't heard about? Finished today at .067c
I think people are buying from old news 8/7/2009 nothing seems to have changed as yet. This stock reminds me of a stock I bought many years ago called AVT lost all my money on it you can look it up on delisted.com It was a great medical breakthrough. Then all of a sudden it went offshore to China then the director disappeared with all our money. Not saying this will happen to this stock but it appears to be the kind of stock that would bounce on any news, medical innovations are very risky stocks its all or nothing when it comes to the FDA. If no new comes out soon it will settle again, buy the way the volumes are not that high this would be traders making some quick dollars trading on gossip and roomers. If you think I am wrong please let me know.
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
Trading Halt from today!! what does this mean for us who hold PRR? could this be good or bad news?
Request for Trading Halt for Prima Biomed Limited
In accordance with ASX Listing Rule 17.1, the directors of Prima Biomed Limited (PRR)
request an immediate trading halt in the securities of the company pending an
announcement to the ASX regarding an investment by a US fund.
The company requests the trading halt remain in place until the opening of trading on
Tuesday 21th July 2009, unless the company makes an announcement before that time.
The company is not aware of any reason why ASX should not grant the request for a
trading halt.
Yours sincerely,
Martin Rogers
Executive Director
Request for Trading Halt for Prima Biomed Limited
In accordance with ASX Listing Rule 17.1, the directors of Prima Biomed Limited (PRR)
request an immediate trading halt in the securities of the company pending an
announcement to the ASX regarding an investment by a US fund.
The company requests the trading halt remain in place until the opening of trading on
Tuesday 21th July 2009, unless the company makes an announcement before that time.
The company is not aware of any reason why ASX should not grant the request for a
trading halt.
Yours sincerely,
Martin Rogers
Executive Director
andione1983
Danger Will Robinson, Danger
- Joined
- 2 February 2009
- Posts
- 41
- Reactions
- 0
Thats marvelous... congrats to all who hod PRR and good luck for next week!!!
All the best!!! Patience will hopefully pay off!
- Joined
- 28 January 2008
- Posts
- 104
- Reactions
- 0
sheesh, you'd have to be a mega-cynic to consider bad news on the eve of so many positive movements and expectations!!
The success of trials to date, the stage that CVAC is at trial-wsie NOW and highly probably buy-in involvement from other Co.s should dispell any thoughts of bad news.
- Joined
- 28 January 2008
- Posts
- 104
- Reactions
- 0
Have a look at the long term trend of PRR; back to 1993. It's a classic chart reflecting the phases of company from inception, through to consolidation and now; growth. why would you want to sell in a growth cycle???